ULTRAGENYX PHARMACEUTICAL INC. Pre-Tax Income
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Pre-Tax Income of -$91.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-05
- ULTRAGENYX PHARMACEUTICAL INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was -$91.00M.
- ULTRAGENYX PHARMACEUTICAL INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was -$184.00M.
- ULTRAGENYX PHARMACEUTICAL INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$127.69M.
- ULTRAGENYX PHARMACEUTICAL INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was -$179.54M.
- ULTRAGENYX PHARMACEUTICAL INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$571.00M.
- ULTRAGENYX PHARMACEUTICAL INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$567.00M.
- ULTRAGENYX PHARMACEUTICAL INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$609.00M.
- ULTRAGENYX PHARMACEUTICAL INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$701.73M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month as first filed | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$91.00M 10-Q · filed 2026-08-05 | -$275.00M 10-Q · filed 2026-08-05 | -$402.69M derived: sum of 3 quarters · filed 2026-08-05 | -$582.23M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | -$184.00M 10-Q · filed 2026-05-06 | -$311.69M derived: sum of 2 quarters · filed 2026-05-06 | -$491.23M derived: sum of 3 quarters · filed 2026-05-06 | -$605.23M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | -$127.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$307.23M derived: sum of 2 quarters · filed 2026-02-18 | -$421.23M derived: sum of 3 quarters · filed 2026-08-05 | -$571.00M 10-K · filed 2026-02-18 | |||
| 2025-09-30 | -$179.54M 10-Q · filed 2025-11-05 | -$293.54M derived: sum of 2 quarters · filed 2026-08-05 | -$443.31M 10-Q · filed 2025-11-05 | -$576.36M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | -$114.00M 10-Q · filed 2026-08-05 | -$114.00M 10-Q · filed 2025-08-06 | -$264.00M 10-Q · filed 2026-08-05 | -$263.77M 10-Q · filed 2025-08-06 | -$396.82M derived: sum of 3 quarters · filed 2026-08-05 | -$530.03M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | -$150.00M 10-Q · filed 2026-05-06 | -$149.77M 10-Q · filed 2025-05-07 | -$282.82M derived: sum of 2 quarters · filed 2026-05-06 | -$416.03M derived: sum of 3 quarters · filed 2026-05-06 | -$546.77M derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | -$132.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$266.03M derived: sum of 2 quarters · filed 2026-02-18 | -$396.77M derived: sum of 3 quarters · filed 2026-02-18 | -$567.00M 10-K · filed 2026-02-18 | -$567.59M 10-K · filed 2025-02-19 | ||
| 2024-09-30 | -$133.21M 10-Q · filed 2025-11-05 | -$263.95M derived: sum of 2 quarters · filed 2025-11-05 | -$434.18M 10-Q · filed 2025-11-05 | -$561.61M derived: sum of 4 quarters · filed 2026-02-18 | |||
| 2024-06-30 | -$130.74M 10-Q · filed 2025-08-06 | -$300.97M 10-Q · filed 2025-08-06 | -$428.40M derived: sum of 3 quarters · filed 2026-02-18 | -$587.40M derived: sum of 4 quarters · filed 2026-02-18 | |||
| 2024-03-31 | -$170.23M 10-Q · filed 2025-05-07 | -$297.66M derived: sum of 2 quarters · filed 2026-02-18 | -$456.66M derived: sum of 3 quarters · filed 2026-02-18 | -$615.75M derived: sum of 4 quarters · filed 2026-02-18 | |||
| 2023-12-31 | -$127.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$286.43M derived: sum of 2 quarters · filed 2026-02-18 | -$445.52M derived: sum of 3 quarters · filed 2026-02-18 | -$609.00M 10-K · filed 2026-02-18 | -$608.46M 10-K · filed 2024-02-21 | ||
| 2023-09-30 | -$159.00M 10-Q · filed 2024-11-06 | -$318.10M derived: sum of 2 quarters · filed 2024-11-06 | -$481.57M 10-Q · filed 2024-11-06 | -$634.86M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-06-30 | -$159.10M 10-Q · filed 2024-08-02 | -$322.57M 10-Q · filed 2024-08-02 | -$475.86M derived: sum of 3 quarters · filed 2025-02-19 | -$714.68M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-03-31 | -$163.48M 10-Q · filed 2024-05-03 | -$316.76M derived: sum of 2 quarters · filed 2025-02-19 | -$555.58M derived: sum of 3 quarters · filed 2025-02-19 | -$713.44M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2022-12-31 | -$153.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$392.10M derived: sum of 2 quarters · filed 2025-02-19 | -$549.96M derived: sum of 3 quarters · filed 2025-02-19 | -$701.73M 10-K · filed 2025-02-19 | |||
| 2022-09-30 | -$238.82M 10-Q · filed 2023-11-03 | -$396.68M derived: sum of 2 quarters · filed 2023-11-03 | -$548.44M 10-Q · filed 2023-11-03 | -$670.88M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-06-30 | -$157.86M 10-Q · filed 2023-08-04 | -$309.62M 10-Q · filed 2023-08-04 | -$432.06M derived: sum of 3 quarters · filed 2024-02-21 | -$504.88M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-03-31 | -$151.76M 10-Q · filed 2023-05-05 | -$274.20M derived: sum of 2 quarters · filed 2024-02-21 | -$347.02M derived: sum of 3 quarters · filed 2024-02-21 | -$468.98M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2021-12-31 | -$122.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | -$195.25M derived: sum of 2 quarters · filed 2024-02-21 | -$317.22M derived: sum of 3 quarters · filed 2024-02-21 | -$452.98M 10-K · filed 2024-02-21 | |||
| 2021-09-30 | -$72.82M 10-Q · filed 2022-11-03 | -$194.78M derived: sum of 2 quarters · filed 2022-11-03 | -$330.54M 10-Q · filed 2022-11-03 | -$354.48M derived: sum of 4 quarters · filed 2023-02-17 | |||
| 2021-06-30 | -$121.97M 10-Q · filed 2022-07-29 | -$257.73M 10-Q · filed 2022-07-29 | -$281.67M derived: sum of 3 quarters · filed 2023-02-17 | -$350.20M derived: sum of 4 quarters · filed 2023-02-17 | |||
| 2021-03-31 | -$135.76M 10-Q · filed 2022-05-06 | -$159.70M derived: sum of 2 quarters · filed 2023-02-17 | -$228.24M derived: sum of 3 quarters · filed 2023-02-17 | -$202.50M derived: sum of 4 quarters · filed 2023-02-17 | |||
| 2020-12-31 | -$23.94M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | -$92.47M derived: sum of 2 quarters · filed 2023-02-17 | -$66.74M derived: sum of 3 quarters · filed 2023-02-17 | -$185.36M 10-K · filed 2023-02-17 | |||
| 2020-09-30 | -$68.53M 10-Q · filed 2021-11-03 | -$42.80M derived: sum of 2 quarters · filed 2021-11-03 | -$161.42M 10-Q · filed 2021-11-03 | -$252.66M derived: sum of 4 quarters · filed 2022-02-15 | |||
| 2020-06-30 | $25.73M 10-Q · filed 2021-08-03 | -$92.89M 10-Q · filed 2021-08-03 | -$184.13M derived: sum of 3 quarters · filed 2022-02-15 | -$296.83M derived: sum of 4 quarters · filed 2022-02-15 | |||
| 2020-03-31 | -$118.62M 10-Q · filed 2021-05-05 | -$209.86M derived: sum of 2 quarters · filed 2022-02-15 | -$322.56M derived: sum of 3 quarters · filed 2022-02-15 | -$421.52M derived: sum of 4 quarters · filed 2022-02-15 | |||
| 2019-12-31 | -$91.24M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | -$203.94M derived: sum of 2 quarters · filed 2022-02-15 | -$302.90M derived: sum of 3 quarters · filed 2022-02-15 | -$399.44M 10-K · filed 2022-02-15 | |||
| 2019-09-30 | -$112.70M 10-Q · filed 2020-10-27 | -$211.66M derived: sum of 2 quarters · filed 2020-10-27 | -$308.20M 10-Q · filed 2020-10-27 | -$395.90M derived: sum of 4 quarters · filed 2021-02-12 | |||
| 2019-06-30 | -$98.96M 10-Q · filed 2020-07-30 | -$195.50M 10-Q · filed 2020-07-30 | -$283.20M derived: sum of 3 quarters · filed 2021-02-12 | -$370.26M derived: sum of 4 quarters · filed 2021-02-12 | |||
| 2019-03-31 | -$96.54M 10-Q · filed 2020-05-07 | -$184.24M derived: sum of 2 quarters · filed 2021-02-12 | -$271.30M derived: sum of 3 quarters · filed 2021-02-12 | -$323.93M derived: sum of 4 quarters · filed 2021-02-12 | |||
| 2018-12-31 | -$87.70M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | -$174.76M derived: sum of 2 quarters · filed 2021-02-12 | -$227.39M derived: sum of 3 quarters · filed 2021-02-12 | -$197.10M 10-K · filed 2021-02-12 | |||
| 2018-09-30 | -$87.06M 10-Q · filed 2019-11-06 | -$139.69M derived: sum of 2 quarters · filed 2019-11-06 | -$109.40M 10-Q · filed 2019-11-06 | -$207.34M derived: sum of 4 quarters · filed 2020-02-14 | |||
| 2018-06-30 | -$52.63M 10-Q · filed 2019-08-02 | -$22.33M 10-Q · filed 2019-08-02 | -$120.28M derived: sum of 3 quarters · filed 2020-02-14 | -$199.50M derived: sum of 4 quarters · filed 2020-02-14 | |||
| 2018-03-31 | $30.29M 10-Q · filed 2019-05-07 | -$67.66M derived: sum of 2 quarters · filed 2020-02-14 | -$146.88M derived: sum of 3 quarters · filed 2020-02-14 | -$219.76M derived: sum of 4 quarters · filed 2020-02-14 | |||
| 2017-12-31 | -$97.95M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-14 | -$177.17M derived: sum of 2 quarters · filed 2020-02-14 | -$250.05M derived: sum of 3 quarters · filed 2020-02-14 | -$318.34M 10-K · filed 2020-02-14 | |||
| 2017-09-30 | -$79.22M 10-Q · filed 2018-11-06 | -$152.10M derived: sum of 2 quarters · filed 2018-11-06 | -$220.39M 10-Q · filed 2018-11-06 | -$291.64M derived: sum of 4 quarters · filed 2019-02-20 | |||
| 2017-06-30 | -$72.88M 10-Q · filed 2018-08-03 | -$141.17M 10-Q · filed 2018-08-03 | -$212.42M derived: sum of 3 quarters · filed 2019-02-20 | -$277.33M derived: sum of 4 quarters · filed 2019-02-20 | |||
| 2017-03-31 | -$68.29M 10-Q · filed 2018-05-08 | -$139.54M derived: sum of 2 quarters · filed 2019-02-20 | -$204.45M derived: sum of 3 quarters · filed 2019-02-20 | -$261.37M derived: sum of 4 quarters · filed 2019-02-20 | |||
| 2016-12-31 | -$71.25M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | -$136.16M derived: sum of 2 quarters · filed 2019-02-20 | -$193.08M derived: sum of 3 quarters · filed 2019-02-20 | -$245.84M 10-K · filed 2019-02-20 | |||
| 2016-09-30 | -$64.91M 10-Q · filed 2017-11-03 | -$121.83M derived: sum of 2 quarters · filed 2017-11-03 | -$174.59M 10-Q · filed 2017-11-03 | ||||
| 2016-06-30 | -$56.92M 10-Q · filed 2017-07-28 | -$109.68M 10-Q · filed 2017-07-28 | |||||
| 2015-12-31 | -$145.62M 10-K · filed 2018-02-21 | ||||||
| 2014-12-31 | -$59.80M 10-K · filed 2017-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |